



Index

Note: Page numbers of article titles are in **boldface** type.

A

- Age factors, in intracerebral hemorrhage outcome, 344
- Albumin, for intracerebral hemorrhage, 336
- Alcohol abuse, intracerebral hemorrhage in, 276, 282, 306–307
- Amphetamine, intracerebral hemorrhage due to, 306
- Amyloid angiopathy, intracerebral hemorrhage in, 270–271, 283, 295, 323
- Anaphylatoxin, in intracerebral hemorrhage, edema due to, 377
- Aneurysms, intracerebral hemorrhage in, 293–294, 303, 329
with arteriovenous malformations, 290–291
- Angiography
for intracerebral hemorrhage, 290
intracerebral hemorrhage due to, 302
- Angioma, venous, intracerebral hemorrhage in, 273–274, 294–295
- Angiopathy, amyloid, intracerebral hemorrhage in, 270–271, 283, 295, 323
- Angioplasty, intracerebral hemorrhage in
carotid percutaneous transluminal, 302
for intracranial atherosclerosis, 302–303
for vasospasm, 303
- Animal models, of intracerebral hemorrhage, **385–393**
bacterial collagenase, 389–390
blood infusion in, 386–389
ischemia-perfusion, 390
pathologic responses in, 385–386
- Anticoagulant therapy, intracerebral hemorrhage in, 305–306
- Antiplatelet therapy, intracerebral hemorrhage in, 306

- Apolipoprotein E, in amyloid angiopathy, intracerebral hemorrhage and, 270–271, 323
- Arteriovenous malformations, intracerebral hemorrhage in, 271–272, 290–291, 303, 324
- Aspiration, in intracerebral hemorrhage, 350
- Aspirin, intracerebral hemorrhage in, 306

B

- Bacterial collagenase model, of intracerebral hemorrhage, 389–390
- Barbiturate coma, for intracerebral hemorrhage, 336
- Bilirubin, formation of, in intracerebral hemorrhage, edema due to, 376–377
- Biliverdin, formation of, in intracerebral hemorrhage, edema due to, 376
- Biopsy, brain, intracerebral hemorrhage in, 300–301
- Blood–brain barrier, disruption of, in intracerebral hemorrhage, edema due to, 285–286, 379
- Blood flow, cerebral. *See* Cerebral blood flow.
- Blood infusion model, of intracerebral hemorrhage, 386–389
- Brain
biopsy of, intracerebral hemorrhage in, 300–301
edema of. *See* Edema, brain.
infarction of, intracerebral hemorrhage after, 275

C

- Capillary telangiectasia, intracerebral hemorrhage in, 295
- Carbon monoxide, formation of, in intracerebral hemorrhage, edema due to, 376–377

Carotid arteries

- endarterectomy of, intracerebral hemorrhage in, 301–302
- percutaneous transluminal angioplasty of, intracerebral hemorrhage in, 302

Cavernous malformations, intracerebral

- hemorrhage in, 272–273, 291–293, 324–325

Cerebral arteries, middle, aneurysm of, rupture of, 293–294

Cerebral blood flow, in intracerebral hemorrhage, **355–370**

- blood pressure effects on, 364–366
- clinical implications of, 364–368
- clinical studies of, 359–363
- hematoma evacuation effects on, 367–368
- in hibernation phase, 363
- in normalization phase, 364
- in reperfusion stage, 363–364
- intracranial pressure reduction and, 366–367
- laboratory studies of, 355–359
- theoretical considerations in, 355

Clot retraction, in intracerebral hemorrhage, edema due to, 372–373

Coagulation cascade, in intracerebral

- hemorrhage, edema due to, 373–374

Coagulopathy, intracerebral hemorrhage in, 275, 305–308, 327–328

Cocaine, intracerebral hemorrhage due to, 295–296, 306, 328–329

Coma, barbiturate, for intracerebral hemorrhage, 336

Complement activation, in intracerebral hemorrhage, edema due to, 285, 377

Computed tomography, in intracerebral hemorrhage, 267, 349–321

- advantages of, 313
- cerebral blood flow and, 359–363
- hypertensive, 321
- in tumors, 325–327
- temporal evolution and, 319–321

Consciousness level, in intracerebral hemorrhage, versus treatment outcome, 343–344

D

Drugs, intracerebral hemorrhage due to, 295–296, 306–307, 328–329

E

Ecstasy, intracerebral hemorrhage due to, 306

Edema, brain, in intracerebral hemorrhage, 267, **371–383**

- blood–brain barrier disruption in, 379
- classification of, 371–372
- clot retraction in, 372–373
- coagulation cascade activation in, 373–374
- complement activation in, 377
- cytotoxic, 371
- hemoglobin degradation products in, 376–377
- hydrostatic pressure and, 372–373
- intact-barrier or open-barrier type of, 371
- interstitial, 371
- mass effect in, 377–378
- mechanisms of, 372–379
- osmotic, 371
- pathology of, 284–286
- red blood cell lysis in, 374–376
- resolution of, 379
- secondary ischemic/reperfusion injury in, 378–379
- time line of, 372
- vasogenic, 371

Encephalitis, intracerebral hemorrhage in, 309

Endarterectomy, carotid, intracerebral hemorrhage in, 301–302

Endoscopy, for intracerebral hemorrhage, 351

Erythrocytes, lysis of, in intracerebral hemorrhage, edema due to, 285–286, 374–376

F

Fibrinolysis, of intracerebral hemorrhage, 351–353

Furosemide, for intracerebral hemorrhage, 336

H

Hemangioma calcificans, 292

Hematoma, evacuation of. *See* Intracerebral hemorrhage, treatment of.

Hemoglobin, formation of, in intracerebral hemorrhage, 313–315, 374–376

Hemophilia, intracerebral hemorrhage in, 307–308

Hemorrhage, intracerebral. *See* Intracerebral hemorrhage.

Heparin, intracerebral hemorrhage due to, 305–306

Hereditary hemorrhagic telangiectasia, intracerebral hemorrhage in, 274–275

Hibernation phase, in intracerebral hemorrhage, 363

Hydrostatic pressure, in intracerebral hemorrhage, edema due to, 372–373

Hyperosmolar therapy, for intracerebral hemorrhage, 336

Hypertension
after intracerebral hemorrhage, 364–366
intracerebral hemorrhage due to, 269, 281–283, 286, 321–323

Hyperventilation, for intracerebral hemorrhage, 335

Hypocholesterolemia, intracerebral hemorrhage in, 275–276, 282

Hypothermia, for intracerebral hemorrhage, 336–337

I

Iatrogenic intracerebral hemorrhage, **299–312**
categories of, 299–300
in alcohol abuse, 276, 282, 306–307
in aneurysm repair, 303
in angioplasty
carotid percutaneous transluminal, 302
for intracranial atherosclerosis, 302–303
for vasospasm, 303
in anticoagulant therapy, 305–306
in antiplatelet therapy, 306
in arteriovenous malformation treatment, 303
in carotid endarterectomy, 301–302
in coagulopathy, 275, 305–308, 327–328
in diagnostic angiography, 302
in drug abuse, 306–307, 328–329
in infections, 309
in intracranial pressure monitoring, 300
in spinal procedures, 301
in stereotactic surgery, 300–301
in thrombocytopenia, 307
in thrombolytic therapy, 275, 303–305
in tumors, 308–309, 325–327

Imaging, of intracerebral hemorrhage, 267–269, **313–334**
cerebral blood flow and, 359–363
computed tomography in. *See* Computed tomography.

magnetic resonance imaging in. *See* Magnetic resonance imaging.

methods for, 313

temporal evolution and, 315–321

versus etiology, 321–330

Infarction, cerebral, intracerebral hemorrhage after, 275

Infections, intracerebral hemorrhage in, 309, 329–330

Intracerebral hemorrhage, **265–279**

animal models of, **385–393**

biochemical evolution of, 313–314

brain edema in, 267, 284–286, **371–383**

cerebral blood flow in, **355–370**

clinical presentation of, 265–267

consciousness level in, versus treatment outcome, 343–344

epidemiology of, 265, 281

etiology of, 313, 321–330

evaluation of, in vascular lesions, 289–290

aneurysms, 293–294

arteriovenous malformation, 271–272, 290

cavernous malformation, 292

hematoma enlargement in, 284

hematoma volume in, versus outcome, 343

iatrogenic, **299–312**

imaging of. *See* Imaging.

in alcoholism, 276, 282, 306–307

in angiography, 302

in angioplasty, 302–303

in carotid procedures, 301–302

in coagulopathy, 275, 305–308, 327–328

in hypocholesterolemia, 275–276, 282

in intracranial pressure monitoring, 300

in spinal procedures, 301

in telangiectasia, 274–275

in thrombolytic therapy, 275, 303–305

in vascular lesions, 271–274, **289–297**

increased intracranial pressure in, **335–338**

location of, versus outcome, 342–343

mechanisms of, 269–271

morbidity and mortality in, 266–267

pathophysiology of, 282–286

risk factors for, 269–276, 281–282

temporal evolution of, 315–321

treatment of, 286

aspiration in, 350

cerebral blood flow changes in, 364–368

endoscopic, 351

fibrinolysis in, 351–353

hypertensive, 322–323

in vascular lesions

Intracerebral hemorrhage (*continued*)
 amyloid angiopathy, 295
 aneurysms, 294
 arteriovenous malformation, 290–291
 cavernous malformation, 292–293
 venous angioma, 295
 intracranial pressure reduction in, **335–338**
 mechanical devices for, 350–351
 medical versus surgical, 286, **339–347**
 nonrandomized controlled studies of, 341–342
 randomized trials of, 339–341
 recommendations for, 344–345
 variables affecting, 342–344
 minimally invasive, **349–354**
 timing of, versus outcome, 343
 with prior infarction, 275

Intracranial pressure
 in intracerebral hemorrhage, reduction of, 366–367
 monitoring of
 in intracerebral hemorrhage, 336
 intracerebral hemorrhage due to, 300

Iron, formation of, in intracerebral hemorrhage, 313–314, 376

Ischemia-perfusion, in intracerebral hemorrhage
 animal model of, 390
 edema due to, 378–379

L

Lipohyalinosis, in intracerebral hemorrhage, 282–283

Lumbar puncture, intracerebral hemorrhage in, 301

M

Magnetic resonance imaging, in intracerebral hemorrhage, 268–269
 advantages of, 313
 hemoglobin byproducts in, 314–315
 hypertensive, 322–323
 in amyloid angiopathy, 323–324
 in arteriovenous malformations, 324
 in cavernous malformations, 324–325
 in tumors, 325–327
 in venous occlusive disease, 329
 temporal evolution and, 315–319

Mannitol, for intracerebral hemorrhage, 336

Membrane attack complex, in intracerebral hemorrhage, edema due to, 377

Microaneurysms, intracerebral hemorrhage in, 283

Minimally invasive therapy, for intracerebral hemorrhage, **349–354**
 endoscopic, 351
 fibrinolysis, 351–353
 mechanical devices for, 350–351
 rationale for, 349–350
 simple aspiration, 350

Moyamoya disease, intracerebral hemorrhage in, 330

Myelography, intracerebral hemorrhage in, 301

Myocardial infarction, thrombolytic therapy for, intracerebral hemorrhage in, 303–304

N

Normalization phase, in intracerebral hemorrhage, 364

O

Oxygen therapy, for intracerebral hemorrhage, 335

Oxyhemoglobin, formation of, in intracerebral hemorrhage, 285–286, 313–315, 374–377

P

Pallidotomy, intracerebral hemorrhage in, 300

Pentobarbital coma, for intracerebral hemorrhage, 336

Percutaneous transluminal carotid angioplasty, intracerebral hemorrhage in, 302

Pituitary apoplexy, 327

Pons, capillary telangiectasia of, 295

Positron emission tomography, in intracerebral hemorrhage, cerebral blood flow and, 359–363

Pregnancy, intracerebral hemorrhage in, 309

Prourokinase, intracerebral hemorrhage caused by, 304–305

R

Radiosurgery, for cavernous malformations, 293

Red blood cells, lysis of, in intracerebral hemorrhage, edema due to, 285–286, 374–376

Rendu-Osler-Weber syndrome, intracerebral hemorrhage in, 274–275

Reperfusion phase, in intracerebral hemorrhage, 363–364

S

Saline solution, for intracerebral hemorrhage, 336

Sedation, for intracerebral hemorrhage, 335

Seizures, in intracerebral hemorrhage, 335

Single-photon emission computed tomography, in intracerebral hemorrhage, cerebral blood flow and, 359–363

Smoking, intracerebral hemorrhage in, 282

SPECT (single-photon emission computed tomography), in intracerebral hemorrhage, cerebral blood flow and, 359–363

Stereotactic techniques
for intracerebral hemorrhage, 350–353
intracerebral hemorrhage due to, 300–301

Stroke
hemorrhagic. *See* Intracerebral hemorrhage.
thrombolytic therapy for, intracerebral hemorrhage in, 304–305

Sympathomimetic drugs, intracerebral hemorrhage due to, 306

T

Telangiectasia, intracerebral hemorrhage in, 274–275, 295

Thalamotomy, intracerebral hemorrhage in, 300

Thrombin formation, in intracerebral hemorrhage, edema due to, 285, 373–374

Thrombocytopenia, intracerebral hemorrhage in, 307

Thrombolytic therapy, intracerebral hemorrhage due to, 275, 303–305

Tissue plasminogen activator
for intracerebral hemorrhage, 382
intracerebral hemorrhage due to, 304–305

Tumors, intracerebral hemorrhage in, 308–309, 325–327

U

Ultrasonic aspirator, for intracerebral hemorrhage, 350–351

Urokinase
for intracerebral hemorrhage, 351–352
intracerebral hemorrhage caused by, 305

V

Vascular lesions, intracerebral hemorrhage in, **289–297**
amyloid angiopathy, 270–271, 283, 295, 323
aneurysms, 293–294, 303, 329
arteriovenous malformations, 271–272, 290–291, 303, 324
capillary telangiectasia, 295
cavernous malformations, 291–293, 324–325
diagnosis of, 289–290
in illicit drug use, 295–296
venous angioma, 273–274, 294–295
venous occlusion, 329

Vasospasm
angioplasty for, intracerebral hemorrhage in, 303
thrombolytic therapy for, intracerebral hemorrhage in, 305

Venous angioma, intracerebral hemorrhage in, 273–274, 294–295

Venous occlusive disease, intracerebral hemorrhage in, 329

Von Willebrand's disease, intracerebral hemorrhage in, 307

W

Warfarin, intracerebral hemorrhage due to, 305–306